Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and/or carbapenem-resistant Enterobacteriaceae infections

American Journal of Infection Control

Volumn 40, Issue 10, 2012, Pages 983-987

  Ku, Kimberly ^a   Pogue, Jason M ^b   Moshos, Judy ^a   Bheemreddy, Suchitha ^a   Wang, Yujing ^a   Bhargava, Ashish ^a   Campbell, Michelle ^a   Khandker, Namir ^a   Lephart, Paul R ^b   Chopra, Teena ^a   Hayakawa, Kayoko ^a   Martin, Emily T ^a   Abreu Lanfranco, Odaliz ^a   Dhar, Sorabh ^a   Kaye, Keith S ^a   Marchaim, Dror ^a  

^a HARPER UNIVERSITY HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

CRE; Gram negative; Klebsiella pneumoniae carbapenemases; KPC; MDR; Multidrug resistant; Polymixin; Tetracycline

Indexed keywords

COLISTIN; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ADULT; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIUM ISOLATE; CARBAPENEM RESISTANT ENTEROBACTERIACEAE INFECTION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; ENTEROBACTERIACEAE INFECTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MIXED INFECTION; MONOTHERAPY; MORTALITY; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; AGED; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; CARBAPENEMS; CASE-CONTROL STUDIES; COHORT STUDIES; COLISTIN; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; MALE; MICHIGAN; MIDDLE AGED; MINOCYCLINE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84870446700     PISSN: 01966553     EISSN: 15273296     Source Type: Journal    
DOI: 10.1016/j.ajic.2011.12.014     Document Type: Article

References (34)

1. A.Y. Peleg, H. Seifert, and D.L. Paterson Acinetobacter baumannii: emergence of a successful pathogen Clin Microbiol Rev 21 2008 538 582
2. E.B. Hirsch, and V.H. Tam Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection J Antimicrob Chemother 65 2010 1119 1125
3. D. Marchaim, T. Chopra, J.M. Pogue, F. Perez, A.M. Hujer, and S. Rudin A colistin-resistant carbapenem-resistant Klebsiella pneumoniae outbreak at metro Detroit Antimicrob Agents Chemother 55 2011 593 599
4. T. Reddy, T. Chopra, D. Marchaim, J.M. Pogue, G. Alangaden, and H. Salimnia Trends in antimicrobial resistance of Acinetobacter baumannii isolates from a metropolitan Detroit health system Antimicrob Agents Chemother 54 2010 2235 2238
5. H.W. Boucher, G.H. Talbot, J.S. Bradley, J.E. Edwards, D. Gilbert, and L.B. Rice Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America Clin Infect Dis 48 2009 1 12
6. J. Fishbain, and A.Y. Peleg Treatment of Acinetobacter infections Clin Infect Dis 51 2010 79 84
7. A.Y. Peleg, and D.C. Hooper Hospital-acquired infections due to gram-negative bacteria N Engl J Med 362 2010 1804 1813
8. L.S. Munoz-Price, and R.A. Weinstein Acinetobacter infection N Engl J Med 358 2008 1271 1281
9. D.E. Karageorgopoulos, and M.E. Falagas New antibiotics: optimal use in current clinical practice Int J Antimicrob Agents 34 Suppl 4 2009 S55 S62
10. J. Li, R.L. Nation, R.W. Milne, J.D. Turnidge, and K. Coulthard Evaluation of colistin as an agent against multi-resistant gram-negative bacteria Int J Antimicrob Agents 25 2005 11 25 (Pubitemid 40023341)
11. J. Rello Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline J Chemother 17 Suppl 1 2005 12 22 (Pubitemid 41686777)
12. J. Gilad, and Y. Carmeli Treatment options for multidrug-resistant Acinetobacter species Drugs 68 2008 165 189
13. A.T. Freire, V. Melnyk, M.J. Kim, O. Datsenko, O. Dzyublik, and F. Glumcher Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia Diagn Microbiol Infect Dis 68 2010 140 151
14. Food and Drug Administration FDA Drug Safety Communication: increased risk of death with Tygacil (tigecycline) compared with other antibiotics used to treat similar infections 2010 Food and Drug Administration Washington [DC]
15. K.B. Anthony, N.O. Fishman, D.R. Linkin, L.B. Gasink, P.H. Edelstein, and E. Lautenbach Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline Clin Infect Dis 46 2008 567 570 (Pubitemid 351263497)
16. Y. Cai, R. Wang, B. Liang, N. Bai, and Y. Liu Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease Antimicrob Agents Chemother 55 2010 1162 1172
17. M. Paul, J. Bishara, A. Levcovich, M. Chowers, E. Goldberg, and P. Singer Effectiveness and safety of colistin: prospective comparative cohort study J Antimicrob Chemother 65 2010 1019 1027
18. R.P. Dellinger, M.M. Levy, J.M. Carlet, J. Bion, M.M. Parker, and R. Jaeschke Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008 Crit Care Med 36 2008 296 327
19. M.E. Charlson, P. Pompei, K.L. Ales, and C.R. MacKenzie A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 1987 373 383 (Pubitemid 17055592)
20. J.F. Bion, S.A. Edlin, G. Ramsay, S. McCabe, and I.M. Ledingham Validation of a prognostic score in critically ill patients undergoing transport Br Med J (Clin Res Ed) 291 1985 432 434 (Pubitemid 15012888)
21. S. Katz, A.B. Ford, R.W. Moskowitz, B.A. Jackson, and M.W. Jaffe Studies of illness in the aged. The index of Adl: a standardized measure of biological and psychosocial function JAMA 185 1963 914 919
22. CLSI Performance standards for antimibrobial susceptibility testing. Nineteenth informational supplement. Approved standard M100-S19 2009 Clinical and Laboratory Standards Institute Wayne [PA]
23. A. Endimiani, J.M. Depasquale, S. Forero, F. Perez, A.M. Hujer, and D. Roberts-Pollack Emergence of blaKPC-containing Klebsiella pneumoniae in a long-term acute care hospital: a new challenge to our healthcare system J Antimicrob Chemother 64 2009 1102 1110
24. A. Endimiani, A.M. Hujer, F. Perez, C.R. Bethel, K.M. Hujer, and J. Kroeger Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA J Antimicrob Chemother 63 2009 427 437
25. J. Breedt, J. Teras, J. Gardovskis, F.J. Maritz, T. Vaasna, and D.P. Ross Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam Antimicrob Agents Chemother 49 2005 4658 4666 (Pubitemid 41552597)
26. CDC Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities MMWR Morb Mortal Wkly Rep 58 2009 256 260
27. T. Reddy, T. Chopra, D. Marchaim, J.M. Pogue, G. Alangaden, and H. Salimnia Trends in antimicrobial resistance of Acinetobacter baumannii isolates from a metropolitan Detroit health system Antimicrob Agents Chemother 54 2010 2235 2238
28. R.L. Nation, and J. Li Colistin in the 21st century Curr Opin Infect Dis 22 2009 535 543
29. M.E. Falagas, and P.I. Rafailidis Nephrotoxicity of colistin: new insight into an old antibiotic Clin Infect Dis 48 2009 1729 1731
30. M.E. Falagas, and P.I. Rafailidis Re-emergence of colistin in today's world of multidrug-resistant organisms: personal perspectives Expert Opin Investig Drugs 17 2008 973 981
31. S.M. Garonzik, J. Li, V. Thamlikitkul, D.L. Paterson, S. Shoham, and J. Jacob Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically-ill patients from a multi-center study provide dosing suggestions for various categories of patients Antimicrob Agents Chemother 55 2011 3284 3294
32. S. Navon-Venezia, A. Leavitt, and Y. Carmeli High tigecycline resistance in multidrug-resistant Acinetobacter baumannii J Antimicrob Chemother 59 2007 772 774 (Pubitemid 47078722)
33. M. Casal, F. Rodriguez, B. Johnson, E. Garduno, F. Tubau, and R.O. de Lejarazu Influence of testing methodology on the tigecycline activity profile against presumably tigecycline-non-susceptible Acinetobacter spp J Antimicrob Chemother 64 2009 69 72
34. C.M. Pillar, D.C. Draghi, M.J. Dowzicky, and D.F. Sahm In vitro activity of tigecycline against gram-positive and gram-negative pathogens as evaluated by broth microdilution and Etest J Clin Microbiol 46 2008 2862 2867